한글목차

B세포 림프종 치료의 동향과 전망

세계 B세포 림프종 치료 시장은 2024년부터 2030년까지 7.8%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년까지 약 102억 8,000만 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 B세포 림프종 이환율 증가와 치료 옵션의 지속적인 발전입니다. 세계 B세포 림프종 치료 시장의 미래는 병원, 전문 클리닉 및 재택치료 시장에서의 비즈니스 기회로 인해 유망합니다.

B세포 림프종 치료 시장 인사이트

루킨텔은 예측 기간 동안 확산성 대세포 B세포 림프종은 환자 수 증가와 B세포 림프종 유병률 증가로 인해 가장 큰 부문을 차지할 것으로 예상했습니다.

이 시장에서 병원은 광범위한 B세포 림프종 치료를 시행하는 데 필요한 시설과 전문성을 제공하기 때문에 가장 큰 시장으로 남을 것으로 보입니다.

북미는 최신 B세포 림프종 치료를 받을 수 있는 의료 시스템이 발달되어 있어 예측 기간 동안 가장 큰 시장으로 남아있을 것으로 보입니다.

시장 규모 및 추정치 : B세포 림프종 치료제 시장 규모를 금액(B달러)으로 추정.

동향 및 예측 분석 : 각 부문별, 지역별 시장 동향(2018-2023년) 및 예측(2024-2030년)을 분석합니다.

부문별 분석 : B세포 림프종 치료제 시장 규모를 유형별, 최종사용자별, 유통채널별, 지역별로 금액(억 달러)으로 추정합니다.

지역별 분석 : B세포 림프종 치료제 시장의 북미, 유럽, 아시아태평양, 기타 지역 및 기타 세계 지역 분석.

전략적 분석 : B세포 림프종 치료제 시장의 유형, 최종 용도, 유통 채널 및 지역별 성장 기회를 분석합니다.

전략 분석 : B세포 림프종 치료제 시장의 M&A, 신제품 개발, 경쟁 구도 등.

Porter's Five Forces 모델을 기반으로 한 산업 경쟁 강도 분석.

이 보고서는 다음과 같은 11가지 주요 질문에 대한 답변을 담고 있습니다.

• Q.1. 시장 부문 중 가장 유망하고 성장성이 높은 기회는 무엇인가?
• Q.2. 어떤 부문이 더 빠른 속도로 성장할 것이며, 그 이유는 무엇인가?
• Q.3. 향후 성장이 가속화될 것으로 예상되는 지역과 그 이유는?
• Q.4. 시장 역학에 영향을 미치는 주요 요인은? 시장의 주요 과제와 비즈니스 리스크는 무엇인가?
• Q.5. 이 시장에서의 비즈니스 리스크와 경쟁 위협은 무엇인가?
• Q.6. 이 시장의 새로운 트렌드와 그 이유는?
• Q.7. 시장에서의 고객 수요 변화에는 어떤 것들이 있는가?
• Q.8. 이 시장의 새로운 발전과 그 발전을 주도하고 있는 기업은?
• Q.9. 이 시장의 주요 기업은? 주요 기업들은 사업 성장을 위해 어떤 전략적 노력을 기울이고 있는가?
• Q.10. 이 시장의 경쟁 제품에는 어떤 것들이 있으며, 소재 및 제품 대체에 따른 시장 점유율 하락의 위협은 어느 정도인가?
• Q.11. 지난 5년간 어떤 M&A가 이루어졌고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 B세포 림프종 치료 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향 및 예측 분석(2018-2030년)

• 거시경제 동향(2018년-2023년)과 예측(2024년-2030년)
• 세계의 B세포 림프종 치료 시장 동향(2018년-2023년)과 예측(2024년-2030년)
• 유형별 세계의 B세포 림프종 치료 시장
  • 미만성 거대 B세포 림프종
  • 림프구성 림프종
  • 털세포 백혈병
  • 원발성 중추신경계 림프종
  • 원발성 안구 내 림프종
  • 기타
• 최종 용도별 세계의 B세포 림프종 치료 시장
  • 병원
  • 전문 클리닉
  • 재택 헬스케어
  • 기타
• 유통 채널별 세계의 B세포 림프종 치료 시장
  • 직접 입찰
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 기타

제4장 지역별 시장 동향 및 예측 분석(2018-2030년)

• 지역별 세계의 B세포 림프종 치료 시장
• 북미의 B세포 림프종 치료 시장
• 유럽의 B세포 림프종 치료 시장
• 아시아태평양의 B세포 림프종 치료 시장
• 기타 지역의 B세포 림프종 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 유형별 세계의 B세포 림프종 치료 시장 성장 기회
  • 최종 용도별 세계의 B세포 림프종 치료 시장 성장 기회
  • 유통 채널별 세계의 B세포 림프종 치료 시장 성장 기회
  • 지역별 세계의 B세포 림프종 치료 시장 성장 기회
• 세계 B세포 림프종 치료 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 B세포 림프종 치료 시장 능력 확대
  • 세계 B세포 림프종 치료 시장의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 유력 기업의 기업 개요

• Pfizer
• Celgene Corporation
• Eli Lilly
• Novartis
• Genentech
• AstraZeneca
• F. Hoffmann-La Roche
• Eisai
• Amgen
• Merck

영문목차

B-Cell Lymphoma Treatment Trends and Forecast

The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets. The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

A more than 150-page report is developed to help in your business decisions.

B-Cell Lymphoma Treatment by Segment

The study includes a forecast for the global B-cell lymphoma treatment by type, end use, distribution channel, and region.

B-Cell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Diffuse Large B-Cell Lymphoma
• Lymphoplasmacytic Lymphoma
• Hairy Cell Leukemia
• Primary Central Nervous System Lymphoma
• Primary Intraocular Lymphoma
• Others

B-Cell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

B-Cell Lymphoma Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

B-Cell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of B-Cell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies B-cell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the B-cell lymphoma treatment companies profiled in this report include-

• Pfizer
• Celgene Corporation
• Eli Lilly
• Novartis
• Genentech
• Astrazeneca
• F. Hoffmann-La Roche
• Eisai
• Amgen
• Merck

B-Cell Lymphoma Treatment Market Insights

Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Within this market, hospital will remain the largest segment as it provides necessary equipment and expertise to perform a wide range of B-cell lymphoma treatments.

North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Features of the Global B-Cell Lymphoma Treatment Market

Market Size Estimates: B-cell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: B-cell lymphoma treatment market size by type, end use, distribution channel, and region in terms of value ($B).

Regional Analysis: B-cell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, distribution channels, and regions for the B-cell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the B-cell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the B-cell lymphoma treatment market size?

Answer: The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030.

Q.2 What is the growth forecast for B-cell lymphoma treatment market?

Answer: The global B-cell lymphoma treatment market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the B-cell lymphoma treatment market?

Answer: The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

Q4. What are the major segments for B-cell lymphoma treatment market?

Answer: The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets.

Q5. Who are the key B-cell lymphoma treatment market companies?

Answer: Some of the key B-cell lymphoma treatment companies are as follows:

• Pfizer
• Celgene Corporation
• Eli Lilly
• Novartis
• Genentech
• Astrazeneca
• F. Hoffmann-La Roche
• Eisai
• Amgen
• Merck

Q6. Which B-cell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that diffuse large B-cell lymphoma is expected to witness highest growth over the forecast period due to fast-growing lymphoma that can affect people of all ages, but it is most common in older adults.Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Q7. In B-cell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the B-cell lymphoma treatment market by type (diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, primary central nervous system lymphoma, primary intraocular lymphoma, and others), end use (hospitals, specialty clinics, home healthcare, and others), distribution channel (direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global B-Cell Lymphoma Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global B-Cell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global B-Cell Lymphoma Treatment Market by Type
  • 3.3.1: Diffuse Large B-Cell Lymphoma
  • 3.3.2: Lymphoplasmacytic Lymphoma
  • 3.3.3: Hairy Cell Leukemia
  • 3.3.4: Primary Central Nervous System Lymphoma
  • 3.3.5: Primary Intraocular Lymphoma
  • 3.3.6: Others
• 3.4: Global B-Cell Lymphoma Treatment Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Specialty Clinics
  • 3.4.3: Home Healthcare
  • 3.4.4: Others
• 3.5: Global B-Cell Lymphoma Treatment Market by Distribution Channel
  • 3.5.1: Direct Tender
  • 3.5.2: Hospital Pharmacy
  • 3.5.3: Retail Pharmacy
  • 3.5.4: Online Pharmacy
  • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global B-Cell Lymphoma Treatment Market by Region
• 4.2: North American B-Cell Lymphoma Treatment Market
  • 4.2.2: North American B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
• 4.3: European B-Cell Lymphoma Treatment Market
  • 4.3.1: European B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
  • 4.3.2: European B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
• 4.4: APAC B-Cell Lymphoma Treatment Market
  • 4.4.1: APAC B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
  • 4.4.2: APAC B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
• 4.5: ROW B-Cell Lymphoma Treatment Market
  • 4.5.1: ROW B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
  • 4.5.2: ROW B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by End Use
  • 6.1.3: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Region
• 6.2: Emerging Trends in the Global B-Cell Lymphoma Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global B-Cell Lymphoma Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global B-Cell Lymphoma Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Celgene Corporation
• 7.3: Eli Lilly
• 7.4: Novartis
• 7.5: Genentech
• 7.6: AstraZeneca
• 7.7: F. Hoffmann-La Roche
• 7.8: Eisai
• 7.9: Amgen
• 7.10: Merck